Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by central nervous system (CNS) lesions from immune attacks on myelin.
• G protein-coupled receptors (GPCRs), particularly cannabinoid receptors, are increasingly targeted for MS therapeutics.

Purpose of the Study:

• To review the role of cannabinoids and their interaction with the endocannabinoid system (ECS) in the context of MS pathology.
• To highlight the therapeutic potential of targeting cannabinoid receptors for MS treatment.

Main Methods:

• Literature review focusing on studies investigating cannabinoids, the ECS, and their effects on CNS immune responses and oligodendrocyte survival in MS.
• Analysis of experimental data on CB1/CB2 receptor agonists and their anti-inflammatory properties.

Main Results:

• Cannabinoids derived from Cannabis sativa may alleviate MS symptoms like pain, tremors, and spasticity.
• Cannabinoids and ECS modulators promote oligodendrocyte survival and myelination, potentially preventing immune-mediated damage in the CNS.
• CB1/CB2 receptor agonists exhibit anti-inflammatory properties relevant to MS treatment.

Conclusions:

• Targeting the ECS and cannabinoid receptors offers a promising therapeutic strategy for managing MS.
• Cannabinoid-based interventions may mitigate the exacerbated immune attack on nerve cells characteristic of MS.